Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
Crossref DOI link: https://doi.org/10.1038/nutd.2014.40
Published Online: 2014-11-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Haas, B
Eckstein, N
Pfeifer, V
Mayer, P
Hass, M D S
Text and Data Mining valid from 2014-11-03
Version of Record valid from 2014-11-03
Article History
Received: 16 June 2014
Revised: 16 September 2014
Accepted: 24 September 2014
First Online: 3 November 2014
Competing interests
: The authors declare no conflict of interest.